Vaccinex, Inc. (VCNX)
OTCMKTS
· Delayed Price · Currency is USD
0.7879
-0.2121 (-21.21%)
Apr 28, 2025, 12:59 PM EDT
Vaccinex Revenue
In the year 2024, Vaccinex had annual revenue of $601.00K with 5.44% growth. Vaccinex had revenue of $213.00K in the quarter ending December 31, 2024.
Revenue
601.00K
Revenue Growth
+5.44%
P/S Ratio
4.01
Revenue / Employee
24.04K
Employees
27
Market Cap
2.41M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 601.00K | 31.00K | 5.44% |
Dec 31, 2023 | 570.00K | 295.00K | 107.27% |
Dec 31, 2022 | 275.00K | -625.00K | -69.44% |
Dec 31, 2021 | 900.00K | 275.00K | 44.00% |
Dec 31, 2020 | 625.00K | 102.00K | 19.50% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.76B |
Veradigm | 588.02M |
Glass House Brands | 200.90M |
Northwest Biotherapeutics | 1.38M |
Elite Pharmaceuticals | 70.00M |
BioStem Technologies | 301.83M |
American Oncology Network | 1.76B |
Silence Therapeutics | 43.26M |
Vaccinex News
- 7 days ago - Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR) - GlobeNewsWire
- 7 weeks ago - Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market - GlobeNewsWire
- 2 months ago - ARMISTICE CAPITAL, LLC Reduces Stake in Vaccinex Inc: A Strategic Portfolio Adjustment - GuruFocus
- 4 months ago - Vaccinex Faces Nasdaq Delisting: What's Going On With The Stock? - Benzinga
- 5 months ago - Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 months ago - Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC - GlobeNewsWire
- 6 months ago - Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting - GlobeNewsWire
- 6 months ago - Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference in Madrid, Spain - GlobeNewsWire